

REMARKS

New claims 23-64 are dependent from claim 20. The new claims are fully supported by the present application including the Drawings and claims as originally filed.

For example, new claims 23-38 feature pharmaceutical products in which nucleic acids are pointed out more particularly. Support for the claims can be found e.g, on page 19, line 20 to page 20, line 10; page 21, line 26 to page 25, line 5.

New claims 39-41 encompass more particular pharmaceutical products in which more specific endothelial cell mitogens are recited. Support for these claims can be found e.g, on page 13, lines 11 to 14; page 18, line 22 to page 19, line 18.

New claims 42-64 feature more particular pharmaceutical products in which EC progenitors are pointed out more precisely. Support for these claims can be found e.g., on page 11, lines 12 through 20; page 14, line 1 to page 15, line 7, page 16, line 3 to page 17, line 18; page 20, line 24 to page 21, line 24; page 25, line 7 to line 22; and page 26, lines 7 through 13.

The USPTO is hereby authorized to charge our deposit account no. 04-1105 for any fee needed to consider this submission including the requisite fee for new claims 23-64.

Early examination of this application is earnestly solicited.

Respectfully submitted,



Robert L. Buchanan, Reg. No.40,927
EDWARDS & ANGELL, LLP
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
130 Water Street
Boston, MA 02109
Tel 617-523-3400
Fax 617-523-6440

Date: 8/30/00
#141973

A